VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.87+2.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VKTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -65.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers
VKTX — earnings miss
Dated 2026-04-29
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Why it matters: If revenue growth falls below the median, it shows a weak trend in healthcare. This affects Viking's outlook.
Worry ifHealthcare sector revenue growth has been below its median for two quarters in a row.
Less concerning ifHealthcare sector revenue growth stays above its median for two consecutive quarters.
Why it matters: Progress in R&D can show future product success and help the company recover.
Supportive ifManagement announces an important milestone in R&D for a key drug.
Worry ifNo updates or delays in R&D progress reported for key drug candidates.
Why it matters: The Health Care sector is maturing. Slowing growth could impact VKTX's performance.
Worry ifHealth Care revenue growth speeds up. It will be above 9% in the next quarter.
Less concerning ifHealth Care revenue growth continues to decelerate below 9%.
Why it matters: Changes in R&D spending show Viking's commitment to its pipeline. This affects future growth.
Supportive ifR&D spending increases by more than 15% in the next quarter.
Worry ifR&D spending decreases or stays flat in the next quarter.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$193 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $532 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,553 loss on $10,000 · 35.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The results will show how well VK2735 works for long-term weight management. Positive data could boost confidence in VK2735's market potential.
Supportive ifData from the VK2735 study shows good weight loss maintenance.
Worry ifThe study shows no good weight loss maintenance or safety issues.
Why it matters: Starting this trial would mark a key step in expanding VK2735's market potential. It could offer a competitive edge with an oral formulation.
Supportive ifAnnouncement of the Phase 3 oral VK2735 trial initiation as planned in Q4 2026.
Worry ifDelay in the initiation of the oral VK2735 trial beyond Q4 2026.
Why it matters: Updates will show how fast Viking is moving on its new obesity treatment. Good news could make investors feel better.
Supportive ifGood news on VK3019's Phase 1 trial results or milestones reached.
Worry ifNegative updates or delays in the VK3019 Phase 1 trial.